Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
Improper handling of the powder might cause it to lose its quality shortly
Provides sustained release
because rigorously controlled human safety data specific to the TB-500 fragment does not exist, its longer-term risk profile, including possible immune reactions, remains unknown Evidence snapshot: Evidence for TB-500 itself is preclinical, drawn mainly from cell-culture and animal studies (a 1999 rat wound-healing study and later rodent cardiac- and tendon-injury models), with a 2026 scoping review describing the musculoskeletal literature on thymosin beta-4 and TB-500 as sparse and largely preclinical
If any side effect persists or worsens, contact your prescriber promptly
The application of GABA and DSIP-CBBBP treatments increases dopamine levels, suggesting a potential neuroprotective or restorative effect, whereas CBBBP and DSIP treatments do not show a significant impact on dopamine levels, indicating their insufficiency in altering dopamine concentrations in this context
US$ 29.83
US$ 29.01
US$ 25.25
US$ 22.17
US$ 26.04
US$ 20.95
US$ 21.86
US$ 22.66
US$ 24.53